Document is current

Article History

Received: 27 August 2025

Accepted: 17 January 2026

First Online: 2 April 2026

Declarations

:

: Institutional review board statement: The study ‘Valine 50 mg/mL and isoleucine 25 mg/mL oral solutions for Maple Syrup Urine Disease (MSUD) – Acceptability and Tolerance Study’ was given favourable ethical approval by the West Midland, South Birmingham Research Ethical Committee (REC reference, 24/WM/0171; IRAS project ID, 324480; ClinicalTrials.gov ID NCT06581991 date 3/9/2024). The study was conducted in adherence with the guidelines of the Local Ethical Committee and in accordance with the ethical standards of the 2024 Helsinki Declaration. Written informed consent and assent for the use of anonymized data was obtained from each participant’s parent or legal guardian.

: Informed Consent Statement: Informed consent was obtained from all subjects involved in the study for publication.

: Anita MacDonald has received research or advisory board funding from Biomarin, PTC Therapeutics, Nutricia, Vitaflo International, Ajinomota Cambrooke, Metax, Applied Pharma Research, MetaHealth, Arla Food Ingredients, Jnana Therapeutics, PIAM, Ipsen Pharma and Galen. Anne Daly Nutricia, Vitaflo International, Ajinomota Cambrooke, Metax, Applied Pharma Research, MetaHealth, Arla Food Ingredients and Galen. Sharon Evans Nutricia, Vitaflo International, Ajinomota Cambrooke, Metax, Applied Pharma Research, MetaHealth, Arla Food Ingredients and Galen. Alex Pinto Nutricia, Vitaflo International, Ajinomota Cambrooke, Metax, Applied Pharma Research, MetaHealth, Arla Food Ingredients and Galen. Catherine Ashmore Nutricia, Vitaflo International, Ajinomota Cambrooke, Metax, Applied Pharma Research, MetaHealth, Arla Food Ingredients and Galen. Martina Tosi has no conflicts of interest.